Spire Wealth Management Acquires 22,750 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Spire Wealth Management raised its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 5,687.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,150 shares of the biopharmaceutical company's stock after purchasing an additional 22,750 shares during the quarter. Spire Wealth Management's holdings in TG Therapeutics were worth $913,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new stake in TG Therapeutics during the 4th quarter valued at $14,508,000. Charles Schwab Investment Management Inc. lifted its holdings in TG Therapeutics by 7.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock valued at $38,212,000 after purchasing an additional 84,904 shares during the last quarter. Norges Bank acquired a new stake in TG Therapeutics during the 4th quarter valued at $12,085,000. Vanguard Group Inc. lifted its holdings in TG Therapeutics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock valued at $469,454,000 after purchasing an additional 209,190 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in TG Therapeutics by 85.4% during the 4th quarter. Wells Fargo & Company MN now owns 331,403 shares of the biopharmaceutical company's stock valued at $9,975,000 after purchasing an additional 152,682 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

Analyst Upgrades and Downgrades

TGTX has been the subject of several research reports. Wall Street Zen raised TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $40.80.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $36.72 on Friday. The stock has a market cap of $5.83 billion, a P/E ratio of 153.00 and a beta of 1.94. The stock has a 50 day simple moving average of $37.05 and a 200 day simple moving average of $34.97. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03. TG Therapeutics, Inc. has a 1-year low of $16.65 and a 1-year high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). The firm had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a return on equity of 18.88% and a net margin of 10.13%. The business's revenue for the quarter was up 90.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.07) earnings per share. Research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction on Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the transaction, the director now directly owns 228,816 shares of the company's stock, valued at $8,452,463.04. The trade was a 4.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.64% of the company's stock.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.